Yan Sun

8PUBLICATIONS
43CO-AUTHORS
Molecular targetsPredictive and prognostic markersStatistical and quantitative geneticsGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 01, 2026
Dynamic genetic and nongenetic RAS-pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.

|Nov 21, 2025
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos

|Nov 17, 2024
Subgroup Identification Based on Quantitative Objectives.

Yan Sun, A S Hedayat

|Aug 12, 2024
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.

Hartmut Döhner, Keith W Pratz, Courtney D DiNardo

|Sep 02, 2022
Predictive signature development based on maximizing the area between receiver operating characteristic curves.

Xin Huang, Lu Tian, Yan Sun

|Aug 25, 2022
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine.

Daniel A Pollyea, Keith W Pratz, Andrew H Wei

Pageof 2

Frequent Collaborators

5 joint publications

Andrew H Wei

5 joint publications

Courtney D DiNardo

3 joint publications

Vladimir Ivanov

3 joint publications

Pau Montesinos